Geode Capital Management
ABUS icon

Geode Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Geode Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17M Buy
3,771,806
+94,499
+3% +$413K ﹤0.01% 2086
2025
Q4 		$17.7M Buy
3,677,307
+11,145
+0.3% +$50.1K ﹤0.01% 2077
2025
Q3 		$16.6M Buy
3,666,162
+29,141
+0.8% +$107K ﹤0.01% 2098
2025
Q2 		$11.2M Buy
3,637,021
+95,876
+3% +$318K ﹤0.01% 2286
2025
Q1 		$12.4M Buy
3,541,145
+59,009
+2% +$197K ﹤0.01% 2159
2024
Q4 		$11.4M Buy
3,482,136
+33,536
+1% +$123K ﹤0.01% 2291
2024
Q3 		$13.3M Buy
3,448,600
+135,442
+4% +$520K ﹤0.01% 2207
2024
Q2 		$10.2M Buy
3,313,158
+354,271
+12% +$1.06M ﹤0.01% 2312
2024
Q1 		$7.63M Buy
2,958,887
+141,192
+5% +$366K ﹤0.01% 2483
2023
Q4 		$7.04M Buy
2,817,695
+120,611
+4% +$236K ﹤0.01% 2523
2023
Q3 		$5.48M Buy
2,697,084
+98,958
+4% +$207K ﹤0.01% 2589
2023
Q2 		$5.98M Buy
2,598,126
+310,213
+14% +$807K ﹤0.01% 2594
2023
Q1 		$6.93M Buy
2,287,913
+156,645
+7% +$442K ﹤0.01% 2478
2022
Q4 		$4.96M Buy
2,131,268
+121,428
+6% +$290K ﹤0.01% 2672
2022
Q3 		$3.84M Buy
2,009,840
+224,798
+13% +$529K ﹤0.01% 2808
2022
Q2 		$4.84M Buy
1,785,042
+55,064
+3% +$141K ﹤0.01% 2717
2022
Q1 		$5.16M Buy
1,729,978
+60,354
+4% +$185K ﹤0.01% 2782
2021
Q4 		$6.49M Buy
1,669,624
+129,193
+8% +$502K ﹤0.01% 2737
2021
Q3 		$6.61M Buy
1,540,431
+253,773
+20% +$846K ﹤0.01% 2750
2021
Q2 		$3.9M Buy
1,286,658
+752,076
+141% +$2.33M ﹤0.01% 3049
2021
Q1 		$1.78M Buy
534,582
+132,931
+33% +$513K ﹤0.01% 3305
2020
Q4 		$1.43M Buy
401,651
+21,274
+6% +$74.5K ﹤0.01% 3249
2020
Q3 		$1.19M Buy
380,377
+67,347
+22% +$205K ﹤0.01% 3140
2020
Q2 		$569K Buy
313,030
+204,634
+189% +$335K ﹤0.01% 3325
2020
Q1 		$109K Sell
108,396
-19,117
-15% -$51.7K ﹤0.01% 3738
2019
Q4 		$354K Buy
127,513
+52,387
+70% +$84.8K ﹤0.01% 3617
2019
Q3 		$114K Sell
75,126
-1,569
-2% -$2.7K ﹤0.01% 3918
2019
Q2 		$159K Sell
76,695
-186,295
-71% -$477K ﹤0.01% 3847
2019
Q1 		$941K Buy
262,990
+27,058
+11% +$104K ﹤0.01% 3183
2018
Q4 		$903K Buy
235,932
+51,127
+28% +$252K ﹤0.01% 3144
2018
Q3 		$1.75M Buy
184,805
+61,017
+49% +$606K ﹤0.01% 2961
2018
Q2 		$903K Buy
123,788
+109,520
+768% +$652K ﹤0.01% 3226
2018
Q1 		$71K Hold
14,268
– – ﹤0.01% 3904
2017
Q4 		$72K Sell
14,268
-12,847
-47% -$75.3K ﹤0.01% 3875
2017
Q3 		$168K Hold
27,115
– – ﹤0.01% 3705
2017
Q2 		$97K Sell
27,115
-378
-1% -$1.3K ﹤0.01% 3849
2017
Q1 		$89K Buy
27,493
+858
+3% +$2.38K ﹤0.01% 3846
2016
Q4 		$65K Buy
26,635
+572
+2% +$1.66K ﹤0.01% 3873
2016
Q3 		$89K Buy
26,063
+143
+0.6% +$559 ﹤0.01% 3829
2016
Q2 		$90K Buy
25,920
+5,717
+28% +$24.2K ﹤0.01% 3820
2016
Q1 		$83 Sell
20,203
-143
-0.7% -$511 ﹤0.01% 3878
2015
Q4 		$90K Buy
20,346
+286
+1% +$1.57K ﹤0.01% 3904
2015
Q3 		$122K Buy
20,060
+2,866
+17% +$25.4K ﹤0.01% 3837
2015
Q2 		$203K Buy
17,194
+5,007
+41% +$76.2K ﹤0.01% 3584
2015
Q1 		$212K Buy
+12,187
New +$250K ﹤0.01% 3558

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management's ABUS Position: Q1 2026 in Review

Geode Capital Management increased its Arbutus Biopharma (ABUS) stake by 2.6% in Q1 2026, buying an estimated $413K and bringing the position to 3,771,806 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Geode Capital Management first reported a position in ABUS in Q1 2015 and has held it in 45 quarters since. The position peaked at $17.7M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Geode Capital Management held 3,771,806 shares of Arbutus Biopharma worth $17M as of Q1 2026.
  • Geode Capital Management bought 94,499 Arbutus Biopharma shares in Q1 2026, an estimated $413K.
  • Arbutus Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2086 holding.
  • Geode Capital Management first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 45 quarters since.
  • Geode Capital Management's Arbutus Biopharma position peaked at $17.7M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.